New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and death.
21 April 2017 | World Health Organization
The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidelines of the International Liver Congress in Amsterdam, will enable competitive supply of RAV in low- and middle-income countries (LMICs) including high prevalence nations Russia, Ukraine, Egypt and Iran.
21 April 2017 | Medicines Patent Pool
At a time when the future of the program is in doubt due to possibly severe budget cuts to the US State Department (where PEPFAR is based) proposed by the new administration, we thought it would be an opportune moment to highlight some of the key studies we have published exploring PEPFAR’s role in fighting the HIV/AIDS epidemic.
19 April 2017 | Health Affairs
Please read and share this letter signed by the European AIDS Treatment Group and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs. It requests Gilead Sciences to surrender their patent of Truvada® or otherwise make it possible for Truvada or generic equivalents of it to be offered at greatly reduced prices to all European health care systems so that it can be used as HIV pre-exposure prophylaxis (PrEP).
18 April 2017 | EATG / PrEP in Europe
A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property's Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair competition by precluding the development and distribution of generic versions of Sofosbuvir at lower prices, said a group of 30 activists led by the Aids Access Foundation and Thai Network of People Living with HIV/Aids.
12 April 2017 | Bangkok Post
The National Aids Council (NAC) has urged Government to consider manufacturing Anti-Retroviral Drugs (ARV) locally, amid fears that budget cuts by the United States will impact on funding.
05 April 2017 | AllAfrica
On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - India.
05 April 2017 | World Health Organization
In January 2017, the Ministry of Finance of the Russian Federation rejected a request to allocate $1.2 billion over four years for the response to HIV, citing “a lack of federal funds.” The Ministry of Health had asked for the funds in order to implement the National AIDS Strategy 2017-2020. The rejection of the funding request once again brought into question the ability and willingness of the Russian Federation to manage its serious HIV epidemic.
04 April 2017 | Global Fund Observer
Treatment for hepatitis C using the key drug sofosbuvir could be vastly scaled up in Brazil after the decision by the National Agency of Health Surveillance (Anvisa) to reject a key patent application on the drug marketed by pharmaceutical corporation Gilead. The decision could pave the way to enable generic competition in Brazil, which should lead to price reductions, making it more affordable to scale up treatment.
03 April 2017 | MSF
New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for the treatment of hepatitis C.
03 April 2017 | Intellectual Property Watch